DRUG SAMPLES SHOULD BE DISCONTINUED, NABP DECLARES IN RESOLUTION
DRUG SAMPLES SHOULD BE DISCONTINUED, NABP DECLARES IN RESOLUTION forwarded to the pharmaceutical industry. The resolution resulted from discussion of diversion-related issues by the Georgia Drugs & Narcotics Agency at the recent annual meeting of the Natl. Assn. of Boards of Pharmacy (NABP). NABP "has been aware of the growing trend in which many drug whslrs. deal in diverted drugs, as well as the number of new drug whslrs. springingup strictly for the purpose of brokering samples and diverted drugs," NABP President-Elect Eugene Argo said in a statement. Argo is a member of the Georgia Pharmacy Board. NABP-urges its member boards "to look closely" at the FBI's Georgia-based investigation of drug diversion, "When a licentiate in their state is convicted of such crimes or otherwise proven to have committed such violations, we urge that state board of pharmacy to take strong, swift and just action," Argo said. The Georgia Pharmacy Board said it plans to introduce legislation in the General Assembly in 1986 banning the sampling of all Rx drugs in Georgia. One of the Georgia board's members is Neil Pruitt, past-president of the Natl. Assn. of Retail Druggists, which has proposed for some time the ban of Rx drug samples. "As a result of this [FBI] investigation and the findings regarding the methods by which drug samples are being misused, it is obvious that it is impossible to insure that the integrity of drug samples have been maintained and have not become adulterated," the Georgia board said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth